Double Aptamer-CRISPR Sensor Quantifies Vancomycin in Blood within 10 Minutes
Background
Vancomycin is a glycopeptide antibiotic used to treat severe gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). It has a narrow therapeutic window, and its pharmacokinetics vary significantly with renal function, age, and comorbidities, making dose adjustment based on blood concentration essential. The recommended minimum serum concentration is generally 10–20 mg/L, or 6.9–13.8 μM in molarity. Too low a concentration risks treatment failure and resistance development, while excessively high levels increase nephrotoxicity or ototoxicity.
Current therapeutic drug monitoring (TDM) for vancomycin employs high-performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and immunoassays. While these methods offer excellent analytical performance, they require expensive equipment, skilled personnel, and complex sample preparation. It can take several hours to obtain results from a laboratory, which is burdensome in settings like intensive care units where rapid dose adjustments are necessary.
CRISPR-Cas12a exhibits trans-cleavage activity, cutting single-stranded DNA in the vicinity of a target DNA, and has been used for high-sensitivity diagnostics. However, low-molecular-weight drugs like vancomycin do not generate DNA signals directly, making direct application of existing CRISPR diagnostic methods challenging. Even when combined with aptamers that bind the drug, the affinity and dissociation rate of a single aptamer have not been sufficient for clinical concentration measurements.
Key Discovery
The research team designed a bivalent aptamer-assisted CRISPR-Cas12a sensor (BACS). First, they predicted vancomycin-binding sites using molecular docking and then stepwise truncated the aptamer sequence to refine its structure. They then rationally designed a linker to connect two identical binding units, creating the bivalent aptamer 2AP33. Compared to a monovalent aptamer, 2AP33 showed higher binding persistence and affinity, acting as a dynamic switch to convert vancomycin concentration changes into Cas12a signals.
The detection principle is competitive binding. The binding state of the aptamer and nucleic acid components differs in the presence and absence of vancomycin, and this change modulates Cas12a trans-cleavage activity. Fluorescent/quenched-labeled single-stranded DNA is cleaved, and the resulting fluorescence intensity is used to calculate drug concentration. The key innovation is linking aptamer molecular recognition with Cas12a signal amplification, bypassing the need for nucleic acid amplification.
The optimized BACS achieved a linear detection range of 1–50 μM and a detection limit of 0.64 μM in clinical serum, covering the recommended minimum concentration range for vancomycin. The analysis time was within 10 minutes. The research team tested 175 clinical serum samples and confirmed high concordance with standard and conventional methods. However, the abstract did not provide correlation coefficients, bias, or discordance rates, so detailed analytical performance must be assessed using the full manuscript data.
Significance and Prospects
BACS has the potential to shift vancomycin TDM from centralized laboratories to bedside or ICU settings. Immediate concentration confirmation after blood draw could allow faster adjustment of dosing intervals and amounts for patients with rapidly changing renal function or those undergoing continuous renal replacement therapy. The simplified operation without high-cost mass spectrometry equipment is also advantageous for small- and medium-sized hospitals and resource-limited healthcare settings.
The 'simulation-cleavage-assembly' design process proposed by the research team is not limited to vancomycin. If aptamers that bind specific drugs or metabolites are available, bivalent aptamers and optimized linkers can be used to develop Cas12a-based sensors. This approach could be extended to other low-molecular-weight drugs with narrow therapeutic windows, such as immunosuppressants and chemotherapeutics, for point-of-care TDM.
Clinical utility has not yet been confirmed. While concordance in 175 serum samples was verified, the study did not assess whether dose adjustments based on sensor results reduce nephrotoxicity or treatment failure. Reproducibility across different hospitals and patient populations, interference from concomitant medications, reagent stability, and inter-device variability must also be evaluated. Multicenter prospective studies defining quality control systems and acceptable error margins relative to standard methods will be necessary for clinical implementation.
Therapeutic drug monitoring (TDM) of vancomycin (VAN) is critical for maximizing efficacy and minimizing toxicity, but conventional methods are constrained by high costs, slow turnaround times, and operational complexity. To address these limitations, we developed a novel Bivalent Aptamer-assisted CRISPR-Cas12a Sensor (termed BACS) for rapid and precise VAN detection. Central to this platform is a high-affinity bivalent aptamer (2AP33), engineered via molecular docking-guided truncation and rational linker design, which exhibits significantly enhanced binding avidity compared to its monovalent counterpart. This aptamer was integrated into a CRISPR-Cas12a system based on a competitive binding mechanism, where target binding modulates Cas12a trans-cleavage activity. The optimized BACS achieved a wide linear detection range (1-50 μM) with a low limit of detection (0.64 μM) in clinical serum, fully covering the clinical therapeutic window. Notably, the assay is rapid (within 10 min), cost-effective, and simple. Critically, the clinical practicality and reliability of BACS were rigorously validated with 175 clinical serum samples, showing exceptional concordance with both the gold standard method and a classical method. This work not only provides a reliable tool for VAN TDM but also offers an adaptable strategy for developing high-performance CRISPR-powered biosensors for diverse clinical analytes through a streamlined molecular engineering pipeline.
Testing serum obtained after vancomycin administration in the ICU using BACS can provide concentration information within 10 minutes, allowing immediate incorporation into the same day's dosing plan. This is particularly beneficial for patients with acute kidney injury, where drug clearance rates can change rapidly, reducing the risk of under- or over-dosing during the waiting period for central laboratory results. In the laboratory, BACS could be used as a rapid screening test while maintaining LC-MS/MS as a confirmatory method.
From an industrial perspective, a product design integrating the aptamer sequence, linker, and Cas12a reagents into a disposable cartridge combined with a compact fluorescence reader is anticipated. However, the claim of 'low cost' must be validated through actual per-test pricing, reagent shelf life, and large-scale production yield. Before regulatory approval, systematic evaluation of serum interferences, cross-reactivity with concomitant antibiotics, inter-laboratory precision, and clinical decision-making criteria is necessary.